#Netherlands #Delft #AdJane #nOMV #Vaccine Platform

AdJane's Breakthrough in Vaccine Technology

AdJane, a pioneering company in clinical-stage vaccine platforms, has recently made headlines by proving the efficacy of its exclusive vaccine technology, known as nOMV (native Outer Membrane Vesicles). This groundbreaking development was reported in a peer-reviewed journal, "Vaccines," following a successful Phase I clinical trial conducted on human subjects. The trial aims to tackle infectious diseases, focusing particularly on the urgent need for improved pandemic preparedness and antimicrobial resistance.

Overview of the Study

The Phase I trial, which involved 40 healthy adult participants, was a randomized, double-blind, placebo-controlled study. It primarily aimed to assess the safety and immune responses generated by a nasal spray vaccine combined with the Spike protein of the SARS-CoV-2 virus. The results have highlighted the platform's ability to safely induce both systemic and mucosal immune responses in humans. Notably, the findings revealed a robust immunological activation at the nasal mucosa, which is vital since this area serves as the primary entry point for various respiratory pathogens.

Anita Gashi, the CEO of AdJane, expressed enthusiasm about the study's outcomes, stating, "Our Phase I findings illustrate that the intranasal OMV vaccine can safely provoke immunity that extends beyond the bloodstream, particularly at the mucosal level, validating our nOMV platform as a promising approach for combatting respiratory infectious diseases."

Addressing Limitations of Current Vaccines

The COVID-19 pandemic exposed significant limitations in the existing injectable vaccines, which, while effective against severe disease, do not adequately prevent infection or transmission at mucosal sites. AdJane's innovative approach seeks to fill this gap by generating immune responses directly at the site of pathogen entry, enhancing overall immunity.

The growing interest in mucosal immunity is reflected in the increasing recognition of mucosal vaccines as an essential tool for global pandemic preparedness. The nOMV platform offers rapid adaptability to emerging respiratory pathogens, allowing for scalable and practical deployment—qualities deemed critical in today’s vaccine landscape.

The nOMV Platform

AdJane’s nOMV platform is anchored in over 30 years of scientific research led by top Dutch public research institutes. It harnesses naturally derived vesicles from the bacteria Neisseria meningitidis, which stimulate the immune system while closely mimicking the surface structures of pathogens. The platform is designed with four proprietary genetic modifications that enhance safety and manufacturing performance while maintaining the vesicles' intrinsic immunostimulatory properties.

This modular technology is equipped to integrate various antigens, facilitating swift development for emerging infectious threats. Currently, AdJane is involved in multiple programs, including key collaborations aimed at securing protection against a wide spectrum of respiratory viruses, supported by CEPI. Additionally, there are applications targeted at combating antimicrobial resistance, exemplified by a CARB-X supported initiative against multi-drug resistant Neisseria gonorrhoeae.

Moreover, the platform has demonstrated remarkable stability, remaining viable under standard refrigeration for over two and a half years, substantially simplifying storage and global deployment without the need for ultra-low temperature supply chains.

Future Implications

With these promising results, AdJane is poised to revolutionize how vaccines can be formulated and administered, particularly in the realm of respiratory infections. By addressing the crucial gaps in mucosal immunity, AdJane’s nOMV platform could alter the landscape of vaccine development, moving toward providing comprehensive protection against diseases.

In recognizing these breakthroughs, we highlight the pressing need for continued investment in vaccine technologies that can adapt to new challenges—ensuring public health systems are equipped to handle future infectious disease threats with resilience.

For further details about the study and its findings, the full results can be accessed in the journal "Vaccines" or through ClinicalTrials.gov under the identifier NCT05604690.